Vir Biotechnology, Inc. (VIR)
Pre-Market: 09:25AM EDT
| Previous Close | 52.31 |
| Open | 51.77 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 51.45 - 53.42 |
| 52 Week Range | 25.31 - 141.01 |
| Volume | 785,820 |
| Avg. Volume | 916,696 |
| Market Cap | 6.871B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.33 |
| Earnings Date | Nov. 08, 2021 - Nov. 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.86 |
- GlobeNewswire
Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that George Scangos, Ph.D., chief executive officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, Sept. 14 at 9:30 a.m. PT / 12:30 p.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the pr
- GlobeNewswire
Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
SAN FRANCISCO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Howard Horn, chief financial officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, Sept. 13, at 4:00 a.m. PT / 7:00 a.m. ET. A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days. The Co
- GlobeNewswire
Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
– First monoclonal antibody authorized in Australia –SAN FRANCISCO, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the first marketing authorization, granted in Australia, for its first commercial product, sotrovimab, developed in partnership with GlaxoSmithKline (GSK). This announcement follows news shared by GSK Australia that the Australian Therapeutic Goods Administration (TGA) has granted provisional marketing authorization for sotrovimab (under the
